SOAT1 and rheumatoid arthritis: Moreover, a blunting effect of the JAK/STAT inhibitor tofacitinib, which is currently indicated in rheumatoid arthritis (RA), psoriatic arthritis, ulcerative colitis, and juvenile idiopathic arthritis (JIA), on oxidized LDL (oxLDL)-induced monocyte adhesion to endothelial cells has been described [10].